As expected, leukocyturia had an adverse impact on treatment outcome for storage symptoms and QOL 1 month after PVP. Postoperative dysuria at 1 month after PVP was observed in 59.6% of the patients with leukocyturia, whereas none of the patients without leukocyturia complained of dysuria. In addition, persistent leukocyturia 3 months after surgery adversely affected the PVR and BVE as well as the treatment outcome for storage symptoms or QOL. In the subset of patients with postoperative leukocyturia, patients without dysuria showed greater improvement in storage symptoms or QOL in the short-term follow-up period after PVP, compared to those with dysuria. Thus, local effects of the laser (photothermal irritation) and prostatic CGP 12177 or edema that developed during PVP may have induced the dysuria or storage symptoms after surgery.10 In the present study, the incidence of dysuria 1 month after PVP was 25.4%, which was concordant with results from other prospective studies (10.9%-93.3%).11, 12 and 13 Interestingly, the patients with leukocyturia but without dysuria had lesser improvement in storage symptoms and QOL after PVP, compared to those without leukocyturia. In some patients with leukocyturia, the prostatic inflammation itself appears to induce storage symptoms, but not dysuria (painful urination). Also, since we performed the PVP using 2 different devices (80W KTP and 120W HPS), this can have an impact on treatment outcomes or the incidence of postoperative leukocyturia. In our study, there was no significant difference in them between the two lasers (data not shown). However, this could be due to the small sample size of 120W HPS group.